title: Stereotactic radiosurgery for the treatment of melanoma and renal cell             carcinoma brain metastases.
abstract: Renal cell carcinoma (RCC) and melanoma brain metastases have traditionally been considered radioresistant lesions when treated with conventional radiotherapeutic modalities. Radiosurgery provides high-dose radiation to a defined target volume with steep fall off in dose at lesion margins. Recent evidence suggests that stereotactic radiosurgery (SRS) is effective in improving local control and overall survival for a number of tumor subtypes including RCC and melanoma brain metastases. The purpose of this study was to compare the response rate to SRS between RCC and melanoma patients and to identify predictors of response to SRS for these 2 specific subtypes of brain metastases. We retrospectively reviewed a prospectively maintained database of all brain metastases treated with Gamma Knife SRS at the University Health Network (Toronto, Ontario) between October 2007 and June 2010, studying RCC and melanoma patients. Demographics, treatment history and dosimetry data were collected; and MRIs were reviewed for treatment response. Log rank, Cox proportional hazard ratio and Kaplan-Meier survival analysis using SPSS were performed. A total of 103 brain metastases patients (41 RCC; 62 melanoma) were included in the study. The median age, Karnofsky performance status score and Eastern Cooperative Oncology Group performance score was 52 years (range 27-81), 90 (range 70-100) and 1 (range 0-2), respectively. Thirty-four lesions received adjuvant chemotherapy and 56 received pre-SRS whole brain radiation therapy. The median follow-up, prescription dose, Radiation Therapy Oncology Group conformity index, target volume and number of shots was 6 months (range 1-41 months), 21 Gy (range 15-25 Gy), 1.93 (range 1.04-9.76), 0.4 cm3 (range 0.005-13.36 cm3) and 2 (range 1-22), respectively. Smaller tumor volume (P=0.007) and RCC pathology (P=0.04) were found to be positive predictors of response. Actuarial local control rate for RCC and melanoma combined was 89% at 6 months, 84% at 12 months, 76% at 18 months and 61% at 24 months. Local control at 12 months was 91 and 75% for RCC and melanoma, respectively. SRS is a valuable treatment option for local control of RCC and melanoma brain metastases. Smaller tumor volume and RCC pathology, predictors of response, suggest distinct differences in tumor biology and the extent of radioresponse between RCC and melanoma.
authors.affiliation: Division of Neurosurgery, University Health Network, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Shelly
authors.initials: S
authors.lastname: Lwu
authors.forename: Pablo
authors.initials: P
authors.lastname: Goetz
authors.forename: Eric
authors.initials: E
authors.lastname: Monsalves
authors.forename: Mandana
authors.initials: M
authors.lastname: Aryaee
authors.forename: Julius
authors.initials: J
authors.lastname: Ebinu
authors.forename: Norm
authors.initials: N
authors.lastname: Laperriere
authors.forename: Cynthia
authors.initials: C
authors.lastname: Menard
authors.forename: Caroline
authors.initials: C
authors.lastname: Chung
authors.forename: Barbara-Ann
authors.initials: BA
authors.lastname: Millar
authors.forename: Abhaya V
authors.initials: AV
authors.lastname: Kulkarni
authors.forename: Mark
authors.initials: M
authors.lastname: Bernstein
authors.forename: Gelareh
authors.initials: G
authors.lastname: Zadeh
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000473:pathology / Q000556:secondary* / Q000628:therapy*; D002292:Carcinoma, Renal Cell / Q000556:secondary*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D017567:Karnofsky Performance Status; D007680:Kidney Neoplasms / Q000473:pathology*; D008297:Male; D008545:Melanoma / Q000556:secondary*; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D016016:Proportional Hazards Models; D016634:Radiosurgery; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D047368:Tumor Burden